Beckman Coulter Introduces Antipsychotic Drug Testing To Evaluate Treatment Response & Adherence

Beckman Coulter, a global clinical diagnostics leader, will introduce new antipsychotic drug tests to laboratories and health care professionals.  The tests measure blood levels of antipsychotic drugs for people taking them to treat schizophrenia or bipolar disorder. The goal is to help health care professionals evaluate consumer treatment adherence and individual consumer drug response.

In a new agreement with Saladax Biomedical, Inc., Beckman Coulter will distribute the tests. These new assays are developed using an innovative nanoparticle technology and empower health care professionals with data to monitor the following antipsychotics: clozapine, risperidone/paliperidone, olanzapine, quetiapine, and aripiprazole.

The rapid, high . . .